Global VEGF Inhibitors for Cancer Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to VEGF Inhibitors for Cancer: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global VEGF Inhibitors for Cancer Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Ramucirumab
1.2.3 Aflibercept
1.2.4 Ramucirumab
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global VEGF Inhibitors for Cancer Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Metastatic colorectal cancer
1.3.3 Metastatic Non-small Cell Lung Cancer
1.3.4 Recurrent Glioblastoma
1.3.5 Cervical Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global VEGF Inhibitors for Cancer Revenue Estimates and Forecasts 2020-2031
2.2 Global VEGF Inhibitors for Cancer Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global VEGF Inhibitors for Cancer Sales Estimates and Forecasts 2020-2031
2.4 Global VEGF Inhibitors for Cancer Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global VEGF Inhibitors for Cancer Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global VEGF Inhibitors for Cancer Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Ramucirumab Market Size by Manufacturers
3.5.2 Aflibercept Market Size by Manufacturers
3.5.3 Ramucirumab Market Size by Manufacturers
3.5.4 Other Market Size by Manufacturers
3.6 Global VEGF Inhibitors for Cancer Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global VEGF Inhibitors for Cancer Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global VEGF Inhibitors for Cancer Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global VEGF Inhibitors for Cancer Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global VEGF Inhibitors for Cancer Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America VEGF Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
6.4 North America VEGF Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America VEGF Inhibitors for Cancer Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe VEGF Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
7.4 Europe VEGF Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe VEGF Inhibitors for Cancer Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific VEGF Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific VEGF Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific VEGF Inhibitors for Cancer Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America VEGF Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
9.4 Central and South America VEGF Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America VEGF Inhibitors for Cancer Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa VEGF Inhibitors for Cancer Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa VEGF Inhibitors for Cancer Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa VEGF Inhibitors for Cancer Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Business Overview
11.1.3 Sanofi VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.1.4 Sanofi VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Sanofi VEGF Inhibitors for Cancer Sales by Product in 2024
11.1.6 Sanofi VEGF Inhibitors for Cancer Sales by Application in 2024
11.1.7 Sanofi VEGF Inhibitors for Cancer Sales by Geographic Area in 2024
11.1.8 Sanofi VEGF Inhibitors for Cancer SWOT Analysis
11.1.9 Sanofi Recent Developments
11.2 Roche
11.2.1 Roche Corporation Information
11.2.2 Roche Business Overview
11.2.3 Roche VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.2.4 Roche VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Roche VEGF Inhibitors for Cancer Sales by Product in 2024
11.2.6 Roche VEGF Inhibitors for Cancer Sales by Application in 2024
11.2.7 Roche VEGF Inhibitors for Cancer Sales by Geographic Area in 2024
11.2.8 Roche VEGF Inhibitors for Cancer SWOT Analysis
11.2.9 Roche Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.3.4 Eli Lilly VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Eli Lilly VEGF Inhibitors for Cancer Sales by Product in 2024
11.3.6 Eli Lilly VEGF Inhibitors for Cancer Sales by Application in 2024
11.3.7 Eli Lilly VEGF Inhibitors for Cancer Sales by Geographic Area in 2024
11.3.8 Eli Lilly VEGF Inhibitors for Cancer SWOT Analysis
11.3.9 Eli Lilly Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.4.4 Pfizer VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pfizer VEGF Inhibitors for Cancer Sales by Product in 2024
11.4.6 Pfizer VEGF Inhibitors for Cancer Sales by Application in 2024
11.4.7 Pfizer VEGF Inhibitors for Cancer Sales by Geographic Area in 2024
11.4.8 Pfizer VEGF Inhibitors for Cancer SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 Celltrion Healthcare
11.5.1 Celltrion Healthcare Corporation Information
11.5.2 Celltrion Healthcare Business Overview
11.5.3 Celltrion Healthcare VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.5.4 Celltrion Healthcare VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Celltrion Healthcare VEGF Inhibitors for Cancer Sales by Product in 2024
11.5.6 Celltrion Healthcare VEGF Inhibitors for Cancer Sales by Application in 2024
11.5.7 Celltrion Healthcare VEGF Inhibitors for Cancer Sales by Geographic Area in 2024
11.5.8 Celltrion Healthcare VEGF Inhibitors for Cancer SWOT Analysis
11.5.9 Celltrion Healthcare Recent Developments
11.6 Amgen
11.6.1 Amgen Corporation Information
11.6.2 Amgen Business Overview
11.6.3 Amgen VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.6.4 Amgen VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Amgen Recent Developments
11.7 Amneal Pharmaceuticals
11.7.1 Amneal Pharmaceuticals Corporation Information
11.7.2 Amneal Pharmaceuticals Business Overview
11.7.3 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.7.4 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Amneal Pharmaceuticals Recent Developments
11.8 Chia Tai Tianqing
11.8.1 Chia Tai Tianqing Corporation Information
11.8.2 Chia Tai Tianqing Business Overview
11.8.3 Chia Tai Tianqing VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.8.4 Chia Tai Tianqing VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Chia Tai Tianqing Recent Developments
11.9 Qilu Pharma
11.9.1 Qilu Pharma Corporation Information
11.9.2 Qilu Pharma Business Overview
11.9.3 Qilu Pharma VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.9.4 Qilu Pharma VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Qilu Pharma Recent Developments
11.10 Boan Biotech
11.10.1 Boan Biotech Corporation Information
11.10.2 Boan Biotech Business Overview
11.10.3 Boan Biotech VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.10.4 Boan Biotech VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Boan Biotech Recent Developments
11.11 Jiangsu Hengrui Pharmaceuticals
11.11.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.11.3 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.11.4 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.12 SinoCellTech
11.12.1 SinoCellTech Corporation Information
11.12.2 SinoCellTech Business Overview
11.12.3 SinoCellTech VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.12.4 SinoCellTech VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 SinoCellTech Recent Developments
11.13 Innovent
11.13.1 Innovent Corporation Information
11.13.2 Innovent Business Overview
11.13.3 Innovent VEGF Inhibitors for Cancer Product Models, Descriptions and Specifications
11.13.4 Innovent VEGF Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Innovent Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 VEGF Inhibitors for Cancer Industry Chain
12.2 VEGF Inhibitors for Cancer Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 VEGF Inhibitors for Cancer Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 VEGF Inhibitors for Cancer Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 VEGF Inhibitors for Cancer Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global VEGF Inhibitors for Cancer Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global VEGF Inhibitors for Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global VEGF Inhibitors for Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global VEGF Inhibitors for Cancer Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global VEGF Inhibitors for Cancer Sales by Region (2020-2025) & (K Units)
Table 8. Global VEGF Inhibitors for Cancer Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global VEGF Inhibitors for Cancer Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global VEGF Inhibitors for Cancer Sales Share by Manufacturers (2020-2025)
Table 12. Global VEGF Inhibitors for Cancer Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global VEGF Inhibitors for Cancer Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global VEGF Inhibitors for Cancer by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitors for Cancer as of 2024)
Table 16. Global VEGF Inhibitors for Cancer Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global VEGF Inhibitors for Cancer Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers VEGF Inhibitors for Cancer Manufacturing Base and Headquarters
Table 19. Global VEGF Inhibitors for Cancer Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global VEGF Inhibitors for Cancer Sales by Type (2020-2025) & (K Units)
Table 23. Global VEGF Inhibitors for Cancer Sales by Type (2026-2031) & (K Units)
Table 24. Global VEGF Inhibitors for Cancer Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global VEGF Inhibitors for Cancer Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global VEGF Inhibitors for Cancer ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global VEGF Inhibitors for Cancer Sales by Application (2020-2025) & (K Units)
Table 29. Global VEGF Inhibitors for Cancer Sales by Application (2026-2031) & (K Units)
Table 30. VEGF Inhibitors for Cancer High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global VEGF Inhibitors for Cancer Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global VEGF Inhibitors for Cancer Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global VEGF Inhibitors for Cancer ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America VEGF Inhibitors for Cancer Growth Accelerators and Market Barriers
Table 37. North America VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America VEGF Inhibitors for Cancer Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe VEGF Inhibitors for Cancer Growth Accelerators and Market Barriers
Table 40. Europe VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe VEGF Inhibitors for Cancer Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific VEGF Inhibitors for Cancer Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific VEGF Inhibitors for Cancer Growth Accelerators and Market Barriers
Table 45. Southeast Asia VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America VEGF Inhibitors for Cancer Investment Opportunities and Key Challenges
Table 47. Central and South America VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa VEGF Inhibitors for Cancer Investment Opportunities and Key Challenges
Table 49. Middle East and Africa VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Sanofi Corporation Information
Table 51. Sanofi Description and Major Businesses
Table 52. Sanofi Product Models, Descriptions and Specifications
Table 53. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Sanofi Sales Value Proportion by Product in 2024
Table 55. Sanofi Sales Value Proportion by Application in 2024
Table 56. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 57. Sanofi VEGF Inhibitors for Cancer SWOT Analysis
Table 58. Sanofi Recent Developments
Table 59. Roche Corporation Information
Table 60. Roche Description and Major Businesses
Table 61. Roche Product Models, Descriptions and Specifications
Table 62. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Roche Sales Value Proportion by Product in 2024
Table 64. Roche Sales Value Proportion by Application in 2024
Table 65. Roche Sales Value Proportion by Geographic Area in 2024
Table 66. Roche VEGF Inhibitors for Cancer SWOT Analysis
Table 67. Roche Recent Developments
Table 68. Eli Lilly Corporation Information
Table 69. Eli Lilly Description and Major Businesses
Table 70. Eli Lilly Product Models, Descriptions and Specifications
Table 71. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Eli Lilly Sales Value Proportion by Product in 2024
Table 73. Eli Lilly Sales Value Proportion by Application in 2024
Table 74. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 75. Eli Lilly VEGF Inhibitors for Cancer SWOT Analysis
Table 76. Eli Lilly Recent Developments
Table 77. Pfizer Corporation Information
Table 78. Pfizer Description and Major Businesses
Table 79. Pfizer Product Models, Descriptions and Specifications
Table 80. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Pfizer Sales Value Proportion by Product in 2024
Table 82. Pfizer Sales Value Proportion by Application in 2024
Table 83. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 84. Pfizer VEGF Inhibitors for Cancer SWOT Analysis
Table 85. Pfizer Recent Developments
Table 86. Celltrion Healthcare Corporation Information
Table 87. Celltrion Healthcare Description and Major Businesses
Table 88. Celltrion Healthcare Product Models, Descriptions and Specifications
Table 89. Celltrion Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Celltrion Healthcare Sales Value Proportion by Product in 2024
Table 91. Celltrion Healthcare Sales Value Proportion by Application in 2024
Table 92. Celltrion Healthcare Sales Value Proportion by Geographic Area in 2024
Table 93. Celltrion Healthcare VEGF Inhibitors for Cancer SWOT Analysis
Table 94. Celltrion Healthcare Recent Developments
Table 95. Amgen Corporation Information
Table 96. Amgen Description and Major Businesses
Table 97. Amgen Product Models, Descriptions and Specifications
Table 98. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Amgen Recent Developments
Table 100. Amneal Pharmaceuticals Corporation Information
Table 101. Amneal Pharmaceuticals Description and Major Businesses
Table 102. Amneal Pharmaceuticals Product Models, Descriptions and Specifications
Table 103. Amneal Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Amneal Pharmaceuticals Recent Developments
Table 105. Chia Tai Tianqing Corporation Information
Table 106. Chia Tai Tianqing Description and Major Businesses
Table 107. Chia Tai Tianqing Product Models, Descriptions and Specifications
Table 108. Chia Tai Tianqing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Chia Tai Tianqing Recent Developments
Table 110. Qilu Pharma Corporation Information
Table 111. Qilu Pharma Description and Major Businesses
Table 112. Qilu Pharma Product Models, Descriptions and Specifications
Table 113. Qilu Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Qilu Pharma Recent Developments
Table 115. Boan Biotech Corporation Information
Table 116. Boan Biotech Description and Major Businesses
Table 117. Boan Biotech Product Models, Descriptions and Specifications
Table 118. Boan Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Boan Biotech Recent Developments
Table 120. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 122. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 123. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 125. SinoCellTech Corporation Information
Table 126. SinoCellTech Description and Major Businesses
Table 127. SinoCellTech Product Models, Descriptions and Specifications
Table 128. SinoCellTech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. SinoCellTech Recent Developments
Table 130. Innovent Corporation Information
Table 131. Innovent Description and Major Businesses
Table 132. Innovent Product Models, Descriptions and Specifications
Table 133. Innovent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Innovent Recent Developments
Table 135. Key Raw Materials Distribution
Table 136. Raw Materials Key Suppliers
Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 138. Milestones in Production Technology Evolution
Table 139. Distributors List
Table 140. Market Trends and Market Evolution
Table 141. Market Drivers and Opportunities
Table 142. Market Challenges, Risks, and Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources


List of Figures
Figure 1. VEGF Inhibitors for Cancer Product Picture
Figure 2. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Ramucirumab Product Picture
Figure 4. Aflibercept Product Picture
Figure 5. Ramucirumab Product Picture
Figure 6. Other Product Picture
Figure 7. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Metastatic colorectal cancer
Figure 9. Metastatic Non-small Cell Lung Cancer
Figure 10. Recurrent Glioblastoma
Figure 11. Cervical Cancer
Figure 12. Other
Figure 13. VEGF Inhibitors for Cancer Report Years Considered
Figure 14. Global VEGF Inhibitors for Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 16. Global VEGF Inhibitors for Cancer Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2020-2031)
Figure 18. Global VEGF Inhibitors for Cancer Sales (2020-2031) & (K Units)
Figure 19. Global VEGF Inhibitors for Cancer Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers VEGF Inhibitors for Cancer Sales Volume Market Share in 2024
Figure 22. Global VEGF Inhibitors for Cancer Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Ramucirumab Revenue Market Share by Manufacturer in 2024
Figure 25. Aflibercept Revenue Market Share by Manufacturer in 2024
Figure 26. Ramucirumab Revenue Market Share by Manufacturer in 2024
Figure 27. Other Revenue Market Share by Manufacturer in 2024
Figure 28. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2020-2031)
Figure 29. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2020-2031)
Figure 30. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2020-2031)
Figure 31. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2020-2031)
Figure 32. North America VEGF Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 33. North America VEGF Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 34. North America Top 5 Manufacturers VEGF Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 35. North America VEGF Inhibitors for Cancer Sales Volume (K Units) by Type (2020- 2031)
Figure 36. North America VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 37. North America VEGF Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 38. North America VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 39. US VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 40. Canada VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 41. Mexico VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 42. Europe VEGF Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 43. Europe VEGF Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Europe Top 5 Manufacturers VEGF Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 45. Europe VEGF Inhibitors for Cancer Sales Volume (K Units) by Type (2020-2031)
Figure 46. Europe VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020-2031)
Figure 47. Europe VEGF Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 48. Europe VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 49. Germany VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 50. France VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 51. U.K. VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 52. Italy VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 53. Russia VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific VEGF Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 55. Asia-Pacific VEGF Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Top 8 Manufacturers VEGF Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 57. Asia-Pacific VEGF Inhibitors for Cancer Sales Volume (K Units) by Type (2020- 2031)
Figure 58. Asia-Pacific VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 59. Asia-Pacific VEGF Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 60. Asia-Pacific VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 61. Indonesia VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 62. Japan VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 63. South Korea VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 64. China Taiwan VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 65. India VEGF Inhibitors for Cancer Revenue (2020-2031) & (US$ Million)
Figure 66. Central and South America VEGF Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 67. Central and South America VEGF Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 68. Central and South America Top 5 Manufacturers VEGF Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 69. Central and South America VEGF Inhibitors for Cancer Sales Volume (K Units) by Type (2021-2031)
Figure 70. Central and South America VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020-2031)
Figure 71. Central and South America VEGF Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 72. Central and South America VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 73. Brazil VEGF Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 74. Argentina VEGF Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 75. Middle East, and Africa VEGF Inhibitors for Cancer Sales YoY (2020-2031) & (K Units)
Figure 76. Middle East and Africa VEGF Inhibitors for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 77. Middle East and Africa Top 5 Manufacturers VEGF Inhibitors for Cancer Sales Revenue (US$ Million) in 2024
Figure 78. Middle East and Africa VEGF Inhibitors for Cancer Sales Volume (K Units) by Type (2021-2031)
Figure 79. South America VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Type (2020-2031)
Figure 80. Middle East and Africa VEGF Inhibitors for Cancer Sales Volume (K Units) by Application (2020-2031)
Figure 81. Middle East and Africa VEGF Inhibitors for Cancer Sales Revenue (US$ Million) by Application (2020-2031)
Figure 82. GCC Countries VEGF Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 83. Turkey VEGF Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 84. Egypt VEGF Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 85. South Africa VEGF Inhibitors for Cancer Revenue (2020-2025) & (US$ Million)
Figure 86. VEGF Inhibitors for Cancer Industry Chain Mapping
Figure 87. Regional VEGF Inhibitors for Cancer Manufacturing Base Distribution (%)
Figure 88. Global VEGF Inhibitors for Cancer Production Market Share by Region (2020-2031)
Figure 89. VEGF Inhibitors for Cancer Production Process
Figure 90. Regional VEGF Inhibitors for Cancer Production Cost Structure
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit